Proteomic analysis of bladder cancer indicates Prx-I as a key molecule in BI-TK/GCV treatment system

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Jiang, Li ^a   Xiao, Xiao ^a   Ren, Jin ^a   Tang, YongYong ^a   Weng, HongQing ^a   Yang, Qi ^a   Wu, MingJun ^a   Tang, Wei ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEROXIREDOXIN 1; SHORT HAIRPIN RNA; THYMIDINE KINASE; TRANSCRIPTION FACTOR RELA; PEROXIREDOXIN; TRANSCRIPTOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIFIDOBACTERIUM LONGUM INFANTIS; BLADDER CANCER; CANCER INHIBITION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEOMICS; RAT; TANDEM MASS SPECTROMETRY; UPREGULATION; WESTERN BLOTTING; ANIMAL; BIFIDOBACTERIUM; CELL CYCLE; CELL PROLIFERATION; DEFICIENCY; DRUG EFFECTS; ENZYMOLOGY; GENE SILENCING; GENE THERAPY; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; URINARY BLADDER NEOPLASMS;

ANIMALS; APOPTOSIS; BIFIDOBACTERIUM; CELL CYCLE; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; GANCICLOVIR; GENE KNOCKDOWN TECHNIQUES; GENETIC THERAPY; NF-KAPPA B; PEROXIREDOXINS; PROTEOMICS; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; THYMIDINE KINASE; TRANSCRIPTOME; URINARY BLADDER NEOPLASMS;

EID: 84902590936     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0098764     Document Type: Article

References (39)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics. CA Cancer J Clin 62: 10-29.
2. American Cancer Society (ACS) (2014) Cancer Facts & Figures 2014. American Cancer Society, Atlanta, GA.
3. Goebell PJ, Knowles MA (2010) Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium. Urol Oncol 28: 409-428.
4. Pasin E, Josephson DY, Mitra AP, Cote RJ, Stein JP (2008) Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Rev Urol 10: 31-43.
5. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
6. Sharma A, Tandon M, Bangari DS, Mittal SK (2009) denoviral vector-based strategies for cancer therapy. Curr Drug ther 4: 117-138.
7. Kimura NT, Taniguchi S, Aoki K, Baba T (1980) Selective localization and growth of Bifidobacterium bifidum in mouse tumors following intravenous administration. Cancer Res 40: 2061-2068. (Pubitemid 10116138)
8. Yazawa K, Fujimori M, Amano J, Kano Y, Taniguchi S (2000) Bifidobacterium longum as a delivery system for cancer gene therapy: selective localization and growth in hypoxic tumors. Cancer Gene Ther 7: 269-274. (Pubitemid 30194562)
9. Yin X, Yu B, Tang Z, He B, Ren J, et al. (2013) Bifidobacterium infantis-mediated HSV-TK/GCV suicide gene therapy induces both extrinsic and intrinsic apoptosis in a rat model of bladder cancer. Cancer Gene Ther 20: 77-81.
10. Tang W, He Y, Zhou S, Ma Y, Liu G (2009) A novel Bifidobacterium infantis-mediated TK/GCV suicide gene therapy system exhibits antitumor activity in a rat model of bladder cancer. J Exp Clin Cancer Res 28: 155.
11. Zhang B, Wang Y, Su Y (2009) Peroxiredoxins a novel target in cancer radiotherapy. Cancer Lett 286: 154-160.
12. Knoops B, Loumaye E, Van Der Eecken V (2007) Evolution of the peroxiredoxins. Subcell Biochem 44: 27-40.
13. Edgar RS, Green EW, Zhao Y, van Ooijen G, Olmedo M, et al. (2012) Peroxiredoxins are conserved markers of circadian rhythms. Nature 486: 459-464.
14. Chae HZ, Oubrahim H, Park JW, Rhee SG, Chock PB (2012) Protein glutathionylation in the regulation of peroxiredoxins: a family of thiol-specific peroxidases that function as antioxidants, molecular chaperones, and signal modulators. Antioxid Redox Signal 16: 506-523.
15. Lowther WT, Haynes AC (2011) Reduction of cysteine sulfinic acid in eukaryotic, typical 2-Cys peroxiredoxins by sulfiredoxin. Antioxid Redox Signal 15: 99-109.
16. Immenschuh S, Baumgart Vogt E (2005) Peroxiredoxins, oxidative stress, and cell proliferation. Antioxid Redox Signal 7: 768-777. (Pubitemid 40563217)
17. Neumann CA, Cao J, Manevich Y (2009) Peroxiredoxin 1 and its role in cell signaling. Cell Cycle 15: 4072-4078.
18. Du ZX, Yan Y, Zhang HY, Liu BQ, Gao YY, et al. (2010) Suppression of MG132-mediated cell death by peroxiredoxin 1 through influence on ASK1 activation in human thyroid cancer cells. Endocr Relat Cancer 17: 553-560.
19. Kim H, Lee TH, Park ES, Suh JM, Park SJ, et al. (2000) Role of peroxiredoxins in regulating intracellular hydrogen peroxide and hydrogen peroxide-induced apoptosis in thyroid cells. J Biol Chem 275: 18266-18270. (Pubitemid 30414779)
20. Fujii J, Ikeda Y (2002) Advances in our understanding of peroxiredoxin, a multifunctional, mammalian redox protein. Redox Rep 7: 123-130. (Pubitemid 34700435)
21. Kinnula VL, Lehtonen S, Sormunen R, Kaarteenaho Wiik R, Kang SW, et al. (2002) Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma. J Pathol 196: 316-323. (Pubitemid 34189421)
22. Lehtonen ST, Svensk AM, Soini Y, Pääkkö P, Hirvikoski P, et al. (2004) Peroxiredoxins, a novel protein family in lung cancer. Int J Cancer 111: 514-521. (Pubitemid 39045317)
23. Noh DY, Ahn SJ, Lee RA, Kim SW, Park IA, et al. (2001) Overexpression of peroxiredoxin in human breast cancer. Anticancer Res 21: 2085-2090.
24. Quan C, Cha EJ, Lee HL, Han KH, Lee KM, et al. (2006) Enhanced expression of peroxiredoxin I and VI correlates with development, recurrence and progression of human bladder cancer. J Urol 174: 1512-1516.
25. Soini Y, Haapasaari KM, Vaarala MH (2011) 8-hydroxydeguanosine and nitrotyrosine are prognostic factors in urinary bladder carcinoma. Int J Clin Exp Pathol 4: 267-275.
26. Yanagawa T, Ishikawa T, Ishii T, Tabuchi K, Iwasa S, et al. (1999) Peroxiredoxin I expression in human thyroid tumors. Cancer Lett 145: 127-132. (Pubitemid 29459080)
27. Yanagawa T, Omura K, Harada H (2005) Peroxiredoxin I expression in tongue squamous cell carcinomas as involved in tumor recurrence. Int J Oral Maxillofac Surg 34: 915-920. (Pubitemid 41644299)
28. Kim HJ, Chae HZ, Kim YJ, Kim YH, Hwangs TS, et al. (2003) Preferential elevation of Prx I and Trx expression in lung cancer cells following hypoxia and in human lung cancer tissues. Cell Biol Toxicol 19: 285-298. (Pubitemid 38002149)
29. Aguilar-Melero P, Prieto-Álamo MJ, Jurado J, Holmgren A, Pueyo C, et al. (2013) Proteomics in HepG2 hepatocarcinoma cells with stably silenced expression of PRDX1. J Proteomics 79: 161-171.
30. Gao MC, Jia XD, Wu QF, Cheng Y, Chen FR, et al. (2011) Silencing Prx1 and/or Prx5 sensitizes human esophageal cancer cells to ionizing radiation and increases apoptosis via intracellular ROS accumulation. Acta Pharmacol Sin 32: 528-536.
31. Riddell JR, Bshara W, Moser MT, Spernyak JA, Foster BA, et al. (2011) Peroxiredoxin 1 controls prostate cancer growth through Toll-like receptor 4-dependent regulation of tumor vasculature. Cancer Res 71: 1637-1646.
32. Woo HA, Chae HZ, Hwang SC, Yang KS, Kang SW, et al. (2003) Reversing the inactivation of peroxiredoxins caused by cysteine sulfinic acid formation. Science 300: 653-656. (Pubitemid 36520592)
33. Hanschmann EM, Godoy JR, Berndt C (2013) Thioredoxins, glutaredoxins, and peroxiredoxins-molecular mechanisms and health significance: from cofactors to antioxidants to redox signaling. Antioxid Redox Signal 19: 1539-1605.
34. Chang TS, Jeong W, Woo HA, Lee SM, Park S, et al. (2004) Characterization of mammalian sulfiredoxin and its reactivation of hyperoxidized peroxiredoxin through reduction of cysteine sulfinic acid in the active site to cysteine. J Biol Chem 279: 50994-51001. (Pubitemid 40017840)
35. Poole LB, Hall A, Nelson KJ (2011) Overview of peroxiredoxins in oxidant defense and redox regulation. Curr Protoc Toxicol Chapter 7:Unit7.9.
36. Rhee SG, Kang SW, Jeong W (2005) Intracellular messenger function of hydrogen peroxide and its regulation by peroxiredoxins. Curr Opin Cell Biol 17: 183-189. (Pubitemid 40380942)
37. Haynes AC, Qian J, Reisz JA, Furdui CM, Lowther WT, et al. (2013) Molecular basis for the resistance of human mitochondrial 2-cys peroxiredoxin 3 to hyperoxidation. J Biol Chem 288: 29714-29723.
38. Hansen JM, Moriarty Craige S, Jones DP (2007) Nuclear and cytoplasmic peroxiredoxin-1 differentially regulate NF-kappaB activities. Free Radic Biol Med 43: 282-288. (Pubitemid 46977170)
39. Wang X, He S, Sun JM (2010) Selective association of peroxiredoxin 1 with genomic DNA and COX-2 upstream promoter elements in estrogen receptor negative breast cancer cells. Mol Biol Cell 21: 2987-2995.